Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on September 22, 2020. The company is an emerging growth company incorporated in California. The report addresses the resumption of its Early Feasibility Study for the Orion Cortical Visual Prosthesis.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational events rather than financial performance.
Material Changes
The primary material change reported is the resumption of in-person clinical study visits for the Orion Cortical Visual Prosthesis at UCLA and the anticipated resumption at Baylor College of Medicine. These visits had been paused in March 2020 due to COVID-19 guidelines. As of the report date, several UCLA participants had been examined.
Outlook, Risks, and Management Commentary
- Study Status: The Early Feasibility Study includes four participants at UCLA and two at Baylor College of Medicine.
- Historical Context: The first human subject was implanted in January 2018, with a total of six subjects implanted to date.
- Risks: The study was previously paused due to the COVID-19 pandemic, highlighting the impact of public health crises on clinical trial timelines.
Investor Verification Checklist
- Verify the current enrollment and safety data for the six implanted subjects in the Orion study.
- Confirm the specific timeline for the resumption of visits at Baylor College of Medicine.
- Review the company's cash runway and capital requirements, as this filing does not disclose financial liquidity.
- Monitor future regulatory filings for updates on the study's progress toward pivotal trials.